BREAST CANCER IS THE MOST COMMON INVASIVE CANCER IN WOMEN WORLDWIDE, WITH ALMOST 1.5 MILLION WOMEN DIAGNOSED IN 2010 ALONE.
Globally, 1 in 10 women will develop the disease at one point in their lives, with that proportion increasing to 1 in 8 in North America, UK, Australia and New Zealand. In the USA alone, every day there are 527 new cases of breast cancer diagnosed, with 110 women succumbing to the disease. The key to breast cancer survival is early detection.
NovoTect™ is a blood-based test for the early diagnosis of breast cancer, and is the first-ever test to stratify Asian patients regardless of sub-type and stage of breast cancer with high specificity and sensitivity.
The NovoTect™ platform technology allows for the early detection of breast cancer by detecting aberrant gene expression in very low copy
numbers of abnormal cells, literally “finding a needle in a haystack” at the early stage of the disease. Unlike current breast cancer diagnostic tests which takes weeks for results, NovoTect™ test results are produced within three hours, significantly increasing its clinical and commercial appeal.
The fundamental nature of the epigenetic mechanisms accorded by the NovoTect™ technology allows for the detection of changes in gene expression irrespective of the abundance or stability of RNA and protein products, which are common targets in other diagnostic tests.
NovoTect™ is significantly set apart from existing diagnostic technologies because it can quickly determine the presence of active breast cancer, as opposed to other tests which make genetic predispositions and assessments.
KEY BENEFITS OF NOVOTECT™
ADVANTAGES AGAINST RNA AND PROTEIN BASED DIAGNOSTIC PRODUCTS
The fundamental nature of the epigenetic mechanisms monitored by the NovoTect™ technology is that it can detect and identify changes in gene expression irrespective of the abundance or stability of RNA and protein products. This offers a significant advantage against RNA and protein-based technologies, which are affected by degradation and the low copy numbers of the monitored targets.
NovoTect™ technology displays high stability and a low degradation rate, because of the unique biochemical properties displayed by epigenetic long range interactions on chromosomal DNA.
The DNA-based read-out of the NovoTect™ technology offers highly sensitive and accurate methods of signal amplification. The technology takes advantage of PCR amplification techniques to monitor novel epigenetic targets As a result, the accuracy of the NovoTect™ test is comparable to the accuracy of PCR-based detection (>97.5%).
The epigenetic mechanisms monitored by the NovoTect™ technology offers highly informative statistically significant read-outs from a minimal number of targets for each test. A validated large-scale trial for a number of genes implicated in the onset and development of breast cancer provides a very high sensitivity and specificity of correct patient stratification (>97%) on only 3 genes (4 epigenetic targets).
NovoTect™ test can utilise all standard types of clinical samples practiced today by clinicians around the world, from paraffin embedded fixed and frozen tissues to whole blood samples stabilised with several common anti-coagulants.